Although inhibitors and their possible role in cancer therapy were our main focus, inducers of the RAS-PI3Kα interaction could also have clinical utility for activating PI3K downstream of receptor tyrosine kinases, for example as a way of promoting tissue regeneration or treating insulin-resistant diabetes (32, 33). The gene discussed is NTRK1; the disease is cancer.